A Phase I/Ib Trial Targeting the Pi3k/Akt Pathway Using Perifosine: Long-Term Progression-Free Survival of Patients With Resistant Neuroblastoma

International Journal of Cancer - United States
doi 10.1002/ijc.30440
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer Development and Progression: Insight to Therapy

Clinical Cancer Drugs
Cancer ResearchToxicologyOncologyPharmaceuticsPharmacology
2016English

Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer

Clinical Cancer Research
Cancer ResearchOncology
2009English

Targeting the PI3K/Akt/mTOR Signalling Pathway in Cystic Fibrosis

Scientific Reports
Multidisciplinary
2017English

Targeting the PI3K/AKT/MTOR Pathway in KSHV-associated Cancers

Infectious Agents and Cancer
Cancer ResearchEpidemiologyOncologyInfectious Diseases
2009English

MicroRNA‑448 Inhibits the Progression of Retinoblastoma by Directly Targeting ROCK1 and Regulating PI3K/AKT Signalling Pathway

Oncology Reports
MedicineCancer ResearchOncology
2018English

Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2012English

PI3K/Akt Signaling Pathway Triggers P2X7 Receptor Expression as a Pro-Survival Factor of Neuroblastoma Cells Under Limiting Growth Conditions

Scientific Reports
Multidisciplinary
2015English

Progression-Free Survival Decreases With Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials

Journal of Cancer
Oncology
2012English

Phase I Clinical Trial of Temsirolimus and Perifosine for Recurrent Glioblastoma

Annals of Clinical and Translational Neurology
NeuroscienceNeurology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy